Although selected older adults with acute myeloid leukemia can benefit from intensive therapies, recent evidences support the use of lower-intensity therapies (hypomethylating agents or low-dose cytarabine) in most of these patients and emphasize the importance of tolerability and quality of life. Individualized approaches to treatment decision-making beyond consideration of chronologic age alone should therefore be considered. One promising strategy is to combine low-intensity treatments with novel agents.
INTRODUCTION
Acute myeloid leukemia (AML) occurs mainly in patients aged 65 years or older. Median age at diagnosis ranges between 68 and 72 years, with approximately one-third of patients aged 75 years or older [1] . There is currently no consensus regarding optimal therapeutic strategy for older adults with AML, who are generally defined as those aged 60 years or older [2, 3] . Intensive chemotherapy has demonstrated a survival advantage over supportive care [2] . However, due to comorbid conditions and disease features, concerns regarding efficacy and toxicity have resulted in the ineligibility of many older patients with AML for this type of treatment [4] . Prognostic models have been developed to determine which older adults are likely to benefit from specific therapies [5] [6] [7] . However, these algorithms are not always easily applicable in daily clinical practice and each model relies on chronological age as a surrogate for measurable patient-specific factors that vary among individuals of similar age. Furthermore, even in patients who can tolerate intensive therapy, outcomes remain poor. Recently published single-center data Electronic supplementary material The online version of this article (doi:10.1007/s40487-015-0006-7) contains supplementary material, which is available to authorized users.
showed a complete remission (CR) rate of 48% after intensive chemotherapy, with median overall survival of 7.4 months and 5-year overall survival of only 10% [8] . Over the last decades, there has been little progress in improving prognosis for patients aged 60 years or older, resulting in unmet needs necessitating novel therapeutic strategies [9] .
This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by the author.
AGING AND AML
Acute myeloid leukemia (AML) is a different disease in older patients. Aging is a complex process influenced by genetic variables as well as environmental factors [10] . Leukemia [12] . Older patients have shown a higher probability of RAS (Rat sarcoma), SRC (Sarcoma), and tumor necrosis factor pathway activation than younger patients, which may contribute to their poorer survival [13] . Leukemia blasts have higher expression of the MRD1 gene, responsible for drug efflux and resistance [14] , and are less likely to undergo apoptosis [15] . Poor outcome in older patients with AML is also correlated with impaired functional and nutritional status, presence of comorbidities, and mental health leading to loss of autonomy after chemotherapy [16] [17] [18] . patients ineligible for intensive chemotherapy [37] . While the first analysis demonstrated a non-significant trend towards improved overall survival in the decitabine arm, an unplanned ad hoc analysis performed 1 year later following 446 deaths showed a significant difference between the two arms of randomization (median overall survival: 7.7 versus 5 months; P = 0.037) [37] 
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NOVEL TREATMENTS IN DEVELOPMENT FOR AML
Novel agents used as single-agent or in combination (Table 1) dose cytarabine alone (30% versus 17%; P = 0.006), but no difference in terms of overall survival [41] . A comparison of clofarabine versus low-dose cytarabine also showed a higher response rate with clofarabine, but no difference in overall survival [42] , while the addition of tipifarnib to low-dose cytarabine was found to have no effect on response or survival [43] . In combination with low-dose cytarabine compared with single-agent clofarabine, CR rate was higher in the first group (67% versus 31%; P = 0.012). Median overall survival was 11.4 months versus 5.8 months (P = 0.10), while median event-free survival was 7.1 versus 1.7 months (P = 0.04) [44] . In combination with azacitidine, gemtuzumab ozogamicin CR rates of 44% and 35% for patients with good-risk or poor-risk AML, respectively [45] . Sapacitabine, a nucleoside analogue prodrug, is currently under investigation in combination with decitabine (ClinicialTrials.gov number, NCT01303796).
Preliminary data demonstrated response in 9/25 patients aged C70 years with newly diagnosed AML [46] . Volasertib, a cell cycle kinase inhibitor, is currently under phase 3 investigation in combination with low-dose cytarabine versus low-dose cytarabine alone (ClinicalTrials.gov number, NCT01721876). In a phase 2, volasertib plus low-dose cytarabine has shown improved efficacy versus low-dose cytarabine with CR rates of 31% versus 13%
(P = 0.05). Median overall survival was also prolonged (8 versus 5.2 months; P = 0.047) [47] . The aurora kinase B inhibitor barasertib is under investigation in combination with lowdose cytarabine (ClincalTrials.gov number, NCT00952588 [52] . Older patients with FLT3 mutant AML should ideally be considered for therapy incorporating a FLT3 inhibitor. The addition of sorafenib, an oral inhibitor of multiple tyrosine kinases including FLT3, to upfront intensive chemotherapy was not beneficial [53] . However, a phase 2 trial of sorafenib combined with azacitidine in FLT3 mutant AML of all ages resulted in an overall response rate of 46% [54] . Based on the discovery of recurrent somatic point mutations in the proteins, has emerged as major epigenetic regulators of proliferation and differentiation. In AML, the inhibition of BRD4 led to cell cycle arrest and apoptosis. A phase 1 clinical trial using the inhibitor OTX015 is currently ongoing [56] . mutations and MLL translocations could identify patients who are most likely to benefit from a certain treatment or dose intensity [57, 58] . However, in multiple studies, patients aged 60 years and older with NPM1-mutated AML have far superior outcomes and survival after intensive therapy compared with any other treatment modality [59] [60] [61] . Presence of the FLT3 mutation was associated with a worse outcome, regardless of NPM1 status [62] . In order to avoid toxicities, hematologists should collaborate more and more with geriatricians to identify clues of vulnerability in elderly patients through the study of functional physical, physiological, cognitive, social and psychological parameters [63] . It appears that chronological age may not be a robust predictor of outcome after accounting for function, comorbidities, and symptoms [64] . These comprehensive geriatric assessments were shown more specific than the screening tool G8, which is the most studied screening tool applied in geriatric oncology [65] . Indeed, systematic measurement of patient-specific factors can help discriminate among fit, vulnerable, and frail patients for a given treatment. Studies have shown that assessment of self-reported activities of daily living and measured physical performance are predictive of survival after accounting for performance status [66, 67] . Better understanding of specific patient vulnerabilities are under evaluation and may help to defined adaptive clinical trial design for specific patient subgroups [68, 69] .
PERSPECTIVES, UNRESOLVED ISSUES, AND CONCLUSIONS
The Townsend index, which measures material deprivation based on unemployment, car ownership, home ownership and overcrowding, was found to be significantly increased in older patients and correlated with survival [70] . Furthermore, a correlation has recently been confirmed between the use of potentially inappropriate medication, polypharmacy (defined as the concurrent use of an excessive number of drugs), and increased comorbidities [71] . Polypharmacy should therefore be a critical component of geriatric evaluation [72] . An important issue remains the lack of a prospective definition of the so called 'unfit' population. Hypomethylating agents or low-dose cytarabine can serve as backbone lowintensity treatments with which novel therapies could be combined. Decision-making should be determined through patient-centered discussions and taken with the aim to keep an accurate balance between efficacy of therapy and avoidance of a decreased quality of life and loss of autonomy feared by elderly patients and their families. Inclusion in clinical trials will furnish some guarantee for quality of treatment, while offering the opportunity to contribute to therapeutic progress [73] .
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